BioSpace News Archive

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD).

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced new clinical drug-drug interaction data for its inhaled antifungal agent, opelconazole, which was presented at ID Week 2023 in Boston, Massachusetts, on October 14, 2023.

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA.

Daré Bioscience, Inc. announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] vaginal gel, 2% in connection with the first commercial sale of the product in the United States, triggering a $1.8 million milestone payment to Daré under its global license agreement with Organon.

Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Phanes Therapeutics, Inc. announced that it has entered into a clinical collaboration agreement with Merck to study PT886, its first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas.

BD announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Lyra Therapeutics, Inc. announced the appointment of Ronan O’Brien, as Chief Legal Officer, effective October 16, 2023.